本研究调查了DARS2表达与{18F-FDG PET/CT}代谢参数之间的相关性，并探讨了DARS2影响肺腺癌（LUAD）细胞增殖和糖酵解的潜在机制。本研究使用基因组学和蛋白质组学分析LUAD样本与对照样本之间DARS2表达差异。对62例在手术前进行{18F-FDG PET/CT}检查的LUAD患者进行了回顾性的相关性分析。采用Spearman相关性分析考察了DARS2表达与PET/CT代谢参数（包括SUVmax、SUVmean、MTV和TLG）之间的关系。此外，通过体外细胞实验分析了干扰DARS2表达对抑制LUAD细胞增殖和糖酵解的分子机制。结果显示，LUAD样本中的DARS2表达显著高于对照样本（p<0.001）。DARS2在LUAD的诊断中具有很高的特异性（98.4%）和敏感性（95.2%）。DARS2表达与SUVmax、SUVmean和TLG呈正相关（p<0.001）。同时，SUVmax在预测LUAD中DARS2过度表达的敏感性和特异性分别为88.9%和65.9%。体外细胞实验显示，干扰DARS2表达可以抑制LUAD细胞的增殖和迁移，促进细胞凋亡，并通过抑制糖酵解相关基因SLC2A1、GPI、ALDOA和PGAM1的表达来抑制肿瘤细胞的糖酵解活性。DARS2的过度表达与{18F-FDG PET/CT}的代谢参数相关，可以提高LUAD的诊断准确性。DARS2可能成为LUAD患者的有用生物标志物，用于诊断、预后和靶向治疗。© 2023 BioMed Central Ltd., part of Springer Nature.

This study investigated the correlation between the expression of DARS2 and metabolic parameters of 18F-FDG PET/CT, and explored the potential mechanisms of DARS2 affecting the proliferation and glycolysis of lung adenocarcinoma (LUAD) cells.This study used genomics and proteomics to analyze the difference in DARS2 expression between LUAD samples and control samples. An analysis of 62 patients with LUAD who underwent 18F-FDG PET/CT examinations before surgery was conducted retrospectively. The correlation between DARS2 expression and PET/CT metabolic parameters, including SUVmax, SUVmean, MTV, and TLG, was examined by Spearman correlation analysis. In addition, the molecular mechanism of interfering with DARS2 expression in inhibiting LUAD cell proliferation and glycolysis was analyzed through in vitro cell experiments.DARS2 expression was significantly higher in LUAD samples than in control samples (p < 0.001). DARS2 has high specificity (98.4%) and sensitivity (95.2%) in the diagnosis of LUAD. DARS2 expression was positively correlated with SUVmax, SUVmean, and TLG (p < 0.001). At the same time, the sensitivity and specificity of SUVmax in predicting DARS2 overexpression in LUAD were 88.9% and 65.9%, respectively. In vitro cell experiments have shown that interfering with DARS2 expression can inhibit the proliferation and migration of LUAD cells, promote cell apoptosis, and inhibit the glycolytic activity of tumor cells by inhibiting the expression of glycolytic related genes SLC2A1, GPI, ALDOA, and PGAM1.Overexpression of DARS2 is associated with metabolic parameters on 18F-FDG PET/CT, which can improve LUAD diagnosis accuracy. DARS2 may be a useful biomarker to diagnose, prognosis, and target treatment of LUAD patients.© 2023. BioMed Central Ltd., part of Springer Nature.